<DOC>
	<DOCNO>NCT01720251</DOCNO>
	<brief_summary>The main objective trial demonstrate efficacy two month pre-seasonal treatment AllerT 100 µg maintenance dose reduce symptom allergic rhinoconjunctivitis follow birch pollen season</brief_summary>
	<brief_title>Efficacy Study Preseasonal Treatment With AllerT Subjects With Birch Pollen Allergy</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>moderate severe allergic rhinoconjunctivitis birch pollen : 1 . Score symptom Rhinoconjunctivitis Symptom Score ( RSS ) ≥ 12 two precede birch pollen season 2 . Previous use antiallergy medication two precede birch pollen season 3 . Positive SPT birch pollen extract 4 . Positive specific IgE CAP test Bet v 1 uncontrolled asthma , FEV1 &lt; 80 % predict previous SIT ( specific immunotherapy ) birch pollen SIT within 5 year clinical symptom due allergen birch pollen whole trial period history anaphylaxis positive skin prick test AllerT treatment condition may increase risk study subject affect efficacy assessment birch pollen season</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>allergic rhinitis</keyword>
	<keyword>birch pollen</keyword>
	<keyword>immunotherapy</keyword>
</DOC>